Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palifermin for GVHD Prevention in Unrelated Donor AlloHSCT
NCT02356159Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Sep 2015
- Primary completion
- Dec 2024
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of palifermin in graft-versus-host disease (GVHD), sponsored by National Cancer Institute. Started Sep 2015; status: completed.
02
Drugs
palifermin
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02356159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356159.